

Management of Pregnancy Related Sepsis

Subject:	Management of Pregnancy related sepsis				
Policy Number					
Ratified By:	Maternity Clinical Guideline and Audit Group				
Date Ratified:	March 2012 (v2)				
Version:	2 nd Edition				
Policy Executive Owner:	Women & Family Services ICSU				
Designation of Author:	Drs Makinde / Siddiqi / Lewith				
Name of Assurance Committee:	Maternity Clinical Guideline and Audit Group				
Date Issued:	June 2015				
Review Date:	June 2018				
Target Audience:	Healthcare staff caring for pregnant women				
Key Words:	Sepsis, Pregnancy				

Version Control Sheet

Version	Date	Author	Status	Comment
2.0	June 2015	Drs Makinde / Siddiqi / Lewith	Active	New 'Obstetric Sepsis/Severe Sepsis Care Pathway'.
				 New 'Is this patient septic?' algorithm. Changes to the recommended treatment regimens.
2.1	Nov 2016	Dr Makinde / Zoe Broadhead		New sepsis criteriaAntibiotics updated
2.2	April 2017	Dr Makinde / Zoe Broadhead		Lactate changes to pathway

Criteria for use

This guideline is to be used for any pregnant woman or woman in the six weeks following delivery, (including those women that have had either a spontaneous or induced miscarriage or termination), with a potential diagnosis of sepsis.

Background/ introduction

Sepsis in pregnant women (or those that have recently delivered) can kill rapidly (sometimes within 12-24 hours of first symptoms) unless identified and treated early.

Sepsis remains a leading contributor to maternal mortality, and was the second most common cause of death in the 2009 - 2012 MMBRRACE-UK report. The report contains the following statement –

'The key actions for the diagnosis and management of sepsis are:

- Timely recognition
- Fast administration of antibiotics
- Quick involvement of experts senior review is essential'

Remember the 'golden hour' – early administration of antibiotics saves lives.

Definitions

Sepsis (related to pregnancy)

In <u>all women</u> who are either pregnant or who have recently delivered or miscarried, who also have a presumed infection, **perform a qSOFA score.** This is a "quick sepsis-related organ failure assessment score" – it is an easy to use bedside scoring system to help identify sepsis. It has replaced SIRS (systemic inflammatory response syndrome) in defining sepsis.

If **2** or more of the following are present the woman has sepsis: it requires immediate treatment.

It is a MEDICAL EMERGENCY

- 1. Systolic B/P < 100
- 2. **Respiratory Rate** \geq 22
- 3. New confusion/ GCS <15

If any of the following red flag symptoms are present, the woman may still have sepsis: if unsure discuss with a senior colleague.

Red flags

- HR ≥ 100
- Lactate ≥ 2 mmol/L
- WCC \ge 17 or \le 4 x 10⁹/L
- Temp \geq 38.3°C or \leq 36°C
- Non blanching rash/ mottled / ashen / cyanotic
- Urine output < 0.5mls/kg/hr /anuria for > 12hrs
- Clinically suspect sepsis

Septic shock (related to pregnancy):

Women who fulfill the above criteria and also have one or more of the following:

- 1. A systolic BP of less than 90mmHg despite 500 ml IV Hartmann's STAT
- 2. Lactate \geq 2 mmol/L

Sepsis is defined as life-threating organ dysfunction caused by a deregulated host response to infection. q SOFA stands for "Quick Sepsis-related Organ Failure
 Assessment" – it is an easy to use bedside scoring system to help identify sepsis. It has replaced SIRS in defining sepsis.

PLEASE REMEMBER ABSENCE OF A FEVER DOES **NOT** EXCLUDE SEPSIS

> Patients at risk

- Clinical history ask about whether the woman or any family members has had a history suggestive of infection: sore throat, abdominal pain, diarrhoea, rigors or breathlessness
- Don't forget the travel history! (consider malaria / Middle East Respiratory Syndrome / Coronavirus)
- First or second trimester miscarriage
- Spontaneous rupture of membranes leading to miscarriage
- Prolonged procedure (if the miscarriage or termination is induced)
- Retained products of conception
- Repeated presentation (to the GP, midwife, or triage) is a worrying sign and should prompt thorough assessment to exclude sepsis.

Look for signs of sepsis in any woman presenting with the criteria above with the following signs and symptoms:

- Abdominal or uterine pain, especially if the pain is constant and severe in a woman who has had a recent termination of pregnancy or spontaneous miscarriage, or if it does not respond to the usual analgesia.
- **Diarrhea** is a common and important sign of pelvic sepsis. Diarrhoea +/- vomiting in a woman with any sign of sepsis is a very serious sign.¹
- Chest pain
- Sore throat
- Spontaneous rupture of membranes (SROM)
- Reduced or absent fetal movements
- A reduced or absent fetal heart (FH) with or without placental abruption may be the result of sepsis.¹
- Abnormal vaginal discharge
- Renal angle pain and tenderness, or a history of kidney stones
- Perineal and breast pain
- Rigors, lethargy, malaise, drowsiness, agitation, disorientation and confusion

Women with sickle cell disease or trait were found to be particularly at risk.

The most important thing is to recognise the woman with sepsis as quickly as possible.

> Potential problems with diagnosis

Women may have been started on antibiotics in the antenatal period in the following situations (please refer to the relevant guidelines) -

- Pre-labour rupture of membranes at term
- Pre-term labour diagnosis and management
- Group B streptococcus infection maternal risk reduction regime

This is to reduce the incidence of infection in the neonate, and not for the treatment of sepsis in the mother.

If you make a diagnosis of SEPSIS please change the antibiotics prescribed in the antenatal period to the appropriate antibiotics, shown in the chart below.

Slide 1 of 2 | "Office Theme" | 🥸



(+) I

日 器 四 平 120% (-)

Whittington Health NHS

ANTIMICROBIAL THERAPY FOR MATERNAL SEPSIS

In all cases, stop any prophylactic antibiotics (eg erythromycin for women with PPROM) and start therapeutic antibiotics as detailed below.

	Clinical situation	First line	Non-severe penicillin allergy (eg delayed rash)	Severe penicillin allergy (eg Anaphylaxis, bronchospasm)	
NANT	Maternal antenatal infection	pl	Ceftriaxone 2g IV OD plus plus 7 Metronidazole 500mg IV TDS 7 0		
PREGNANT	Maternal antenatal sepsis	pl Metronidazole pl Gentamicin 2mg/kg IV S	e 2g IV OD us 500mg IV TDS us STAT + 1.5mg/kg IV TDS Brd or 4th dose. Aim for trough level < 2mg/L)	Clindamycin 600mg IV QDS plus Gentamicin 2mg/kg IV STAT + 1.5mg/kg IV TDS (Take trough levels immediately before the 3rd or 4th dose. Aim for trough level < 2mg/L)	
DELIVERY	Postpartum infection	Co-amoxiclav 1.2g IV TDS	Ceftriaxone 2g IV OD plus Metronidazole 500mg IV TDS	Clindamycin 600mg IV QDS plus Gentamicin 7mg/kg IV OD (Take a single blood sample 6 to 14 hours after the first dose. Refer to the Hartford Nomogram)	
POST DELI	Postpartum sepsis	Co-amoxiclav 1.2g IV TDS plus Gentamicin 7mg/kg IV OD (Take a single blood sample 6 to 14 hours after the first dose. Refer to the Hartford Nomogram)	Ceftriaxone 2g IV OD plus Metronidazole 500mg IV TDS plus Gentamicin 7mg/kg IV OD (Take a single blood sample 6 to 14 hours after the first dose. Refer to the Hartford Nomogram)	Clindamycin 600mg IV QDS plus Gentamicin 7mg/kg IV OD (Take a single blood sample 6 to 14 hours after the first dose. Refer to the Hartford Nomogram)	

All antimicrobial prescription should be for <u>24 hours only and then reviewed.</u>

Patient should be discussed with Microbiology team within daylight hours as soon as possible.

WHAT IS qSOFA? WHAT IS SEPSIS?

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. qSOFA stands for "Quick Sepsisrelated Organ Failure Assessment". qSOFA is an easy to use bedside scoring system to help identify sepsis. It has replaced SIRS in defining sepsis.

> E. Prescribing on JAC – sepsis Protocol

🖞 POE - Pres	scriber Order Entry		[MS	ZOE BROADHE	AD]					Retain					8 23
ANOTHER TE	ST									Ward				PHI	JAG
Consultant	DR SIMON LEWIS				-	Ward M	ERCERS (Z	WH)			•]				
Hospital No.	A02062057	Nat. No.		Date of	Birth 11-J	an-1980	Age 36	yrs	Height 158	cm We	ight 65.0	00 k	ig BSA	1.66	sq m
Allergies Details	metronidazole	(-	44												
	e Medications Discontin s Drug Name	 Drug Select Search Option Prescriber 	ins	proved 🔘 Prop	rietary 🔘) Treatmer	nt Protocols			РНМ	₹ JA	53 C	Stop Dat	te/Time	BNF
R	IBUPROFEN 400 mg PARACETAMOL 500 WARFARIN - See Ser							Rout < <al< td=""><td>te L ROUTES>></td><td>•</td><td>Sear</td><td>ch 6</td><td>5) 23-Oct-2</td><td>016 08:01</td><td>Musculoskele Central nervo Cardiovasculi</td></al<>	te L ROUTES>>	•	Sear	ch 6	5) 23-Oct-2	016 08:01	Musculoskele Central nervo Cardiovasculi
CITS		SEPSIS SEPSIS SEPSIS SEPSIS SEPSIS SEPSIS SEPSIS	S - ANTENATA S - GRAM NEG S - INTRA-ABE S - INTRA-ABE S - INTRA-ABE S - MENINGITI S - MENINGITI	L (1ST LINE/NO L (SEVERE PEN BATIVE RESISTA DOMINAL (1ST LI DOMINAL (1ST LI DOMINAL (SEVEF S (1ST LINE/NO S (SEVERE PEN ENIC (1ST LINE)	ICILLIN ALI NT ORGAI NE) SEVERE PE RE PENICIL N-SEVERE ICILLIN ALI	LERGY SE NISM SE ENICILI SE LIN AL SE PENIC SE LERGY SE	EPSIS - ANT EPSIS - GRJ EPSIS - INT EPSIS - INT EPSIS - INT EPSIS - MEI EPSIS - MEI	ENATA AM NEG RA-ABD RA-ABD RA-ABD IINGITI	AL (SEVERE P BATIVE RESIS DOMINAL (1ST DOMINAL (NO DOMINAL (SE DOMINAL (SE S (1ST LINE/	ENICILLIN / STANT ORG FLINE) N-SEVERE VERE PENI VON-SEVER ENICILLIN /	ALLERC SANISM PENIC CILLIN . RE PEN	•			
Pat	lect Hgt/Wgt Entry	Allergy	Conflict Log	Notes 4	Add Order	Modif Orde	r Ver	fication	Discontinu Order	Ord	er	Resum Order		Clos	e
1.	tails Lab Results	Previous Meds.	Clinical Info	C)ischarge	Short Te	2 C C C C C C C C C C C C C C C C C C C	dmin. Chart	Charting	Ord	5000 C	All Orde	ers	Hel	P

> References (evidence upon which the guideline is based)

- 1. Saving Lives, improving mothers' care Lessons learned to improve maternity care from UK and Ireland Confidential Enquires into Maternal Deaths and Morbidity 2009 2012 MBRRACE-UK
- 2. McClure JH, Cooper GM, Clutton-Brock TH. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006-8: a review. Br J Anaesth 2011; 107: 127-32
- 3. Dellinger, RP et al (2008) "Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock", Critical Care Medicine Vol 36, No 1, pp 296-327
- 4. Singer M et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315 (8):801-810.
- 5. 'Sepsis: Just Say Sepsis!', National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 2015 available at NCEPOD website

Compliance with this guideline (how and when the guideline will be monitored e.g. audit and which committee the results will be reported to) Please use the tool provided at the end of this template

To be completed and attached to any procedural document when submitted to the appropriate committee for consideration and approval

		Yes/No	Comments
1.	Does the procedural document affect one group less or more favourably than another on the basis of:		
	Race	No	
	 Ethnic origins (including gypsies and travellers) 	No	
	Nationality	No	
	• Gender	No	
	Culture	No	
	Religion or belief	No	
	Sexual orientation including lesbian, gay and bisexual people	No	
	• Age	No	
	 Disability - learning disabilities, physical disability, sensory impairment and mental health problems 	No	
2.	Is there any evidence that some groups are affected differently?	No	
3.	If you have identified potential discrimination, are any exceptions valid, legal and/or justifiable?	No	
4.	Is the impact of the procedural document likely to be negative?	No	
5.	If so can the impact be avoided?	N/A	
6.	What alternatives are there to achieving the procedural document without the impact?	N/A	
7.	Can we reduce the impact by taking different action?	N/A	

If you have identified a potential discriminatory impact of this procedural document, please refer it to the Director of Human Resources, together with any suggestions as to the action required to avoid/reduce this impact.

For advice in respect of answering the above questions, please contact the Director of Human Resources.

Checklist for the Review and Approval of Procedural Document

To be completed and attached to any procedural document when submitted to the relevant committee for consideration and approval.

	Title of document being reviewed:	Yes/No	Comments
1.	Title		
	Is the title clear and unambiguous?	Yes	
	Is it clear whether the document is a guideline, policy, protocol or standard?	Yes	
2.	Rationale		
	Are reasons for development of the document stated?	Yes	
3.	Development Process		
	Is it clear that the relevant people/groups have been involved in the development of the document?	Yes	
	Are people involved in the development?	Yes	
	Is there evidence of consultation with stakeholders and users?	Yes	
4.	Content		
	Is the objective of the document clear?	Yes	
	Is the target population clear and unambiguous?	Yes	
	Are the intended outcomes described?	Yes	
5.	Evidence Base		
	Are key references cited in full?	N/A	
	Are supporting documents referenced?	N/A	
6.	Approval		
	Does the document identify which committee/ group will approve it?	Yes	
7.	Dissemination and Implementation		
	Is there an outline/plan to identify how this will be done?	Yes	
8.	Document Control		
	Does the document identify where it will be held?	Yes	
9.	Process to Monitor Compliance and Effectiveness		
	Are there measurable standards or KPIs to support the monitoring of compliance with and	Yes	

	Title of document being reviewed:	Yes/No	Comments
	effectiveness of the document?		
	Is there a plan to review or audit compliance with the document?	Yes	
10.	Review Date		
	Is the review date identified?	Yes	
	Is the frequency of review identified? If so is it acceptable?	Yes	
11.	Overall Responsibility for the Document		
	Is it clear who will be responsible for co- ordinating the dissemination, implementation and review of the document?	Yes	

Executive Spo	onsor Approval							
If you approve the document, please sign and date it and forward to the author. Procedural documents will not be forwarded for ratification without Executive Sponsor Approval								
Name	Date							
Signature								
Relevant Com	mittee Approval							
	f Nursing and Patient Experience's signature appropriate Governance Committee.	below confire	ms that this procedural document was					
Name		Date						
Signature								
Responsible C	Committee Approval – only applies to review	ed procedur	al documents with minor changes					
The Committee Committee	e Chair's signature below confirms that this p	rocedural doo	cument was ratified by the responsible					
Name		Date						
Name of Committee		Name & role of Committee Chair						
Signature								

Tool to Develop Monitoring Arrangements for Policies and guidelines

What key element(s) need(s) monitoring as per local approved policy or guidance?	Who will lead on this aspect of monitoring? Name the lead and what is the role of the multidisciplinary team or others if any.	What tool will be used to monitor/check/observe/Asses s/inspect/ authenticate that everything is working according to this key element from the approved policy?	How often is the need to monitor each element? How often is the need complete a report ? How often is the need to share the report?	What committee will the completed report go to?
Element to be monitored	Lead	ΤοοΙ	Frequency	Reporting arrangements
Ensure the Obstetric Sepsis / Severe Sepsis Care Pathway is commenced appropriately Ensure Antibiotics are commenced within one hour of diagnosis	Lead Obstetrician for Labour Ward	In-house audit tool	An individualised review date as low frequency event	 These reports will be reviewed by the Maternity Clinical Guidelines and Audit Group. It is their responsibility to monitor the findings from each report. Evidence to support this will be found in the form minutes. Key factors to be noted are: Audit findings Deficiencies Whether this is improvement from previous audit findings Action planning with a named person who is responsible Next date where an update will be given and by whom